Evaluation and management of drug-eluting stent in-stent restenosis

Curr Opin Cardiol. 2023 Sep 1;38(5):433-440. doi: 10.1097/HCO.0000000000001073. Epub 2023 Jul 13.

Abstract

Purpose of review: In-stent restenosis (ISR) is the most common cause of stent failure. Although the rate of ISR is significantly lower with contemporary drug-eluting stents (DES), it remains a challenging clinical entity to treat.

Recent findings: In this review, we focus on a practical approach to management of DES ISR with intravascular imaging at its core, as supported by several recently published articles. This facilitates assessment of the underlying mechanism(s) essential to the successful treatment of ISR allowing for a tailored selection of treatment modalities.

Summary: The successful treatment of DES ISR requires identification of the causative mechanism(s). Individualized treatment may include high-pressure balloon angioplasty alone, cutting or scoring balloons, intravascular lithotripsy, atheroablative therapies and a selection of either repeat DES implantation or drug-coated balloon treatment.

Publication types

  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary* / adverse effects
  • Coronary Angiography
  • Coronary Restenosis* / etiology
  • Coronary Restenosis* / therapy
  • Drug-Eluting Stents* / adverse effects
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Prosthesis Design
  • Treatment Outcome